Journal of Cancer Therapy

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org
Citations    
"The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme"
written by Stanislaw R. Burzynski, Sonali S. Patil,
published by Journal of Cancer Therapy, Vol.5 No.10, 2014
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways …
Drug Development Research, 2024
[2] Newly diagnosed Anaplastic Astrocytoma:> 23 Year Survival in a 31-Year and 11-Month-Old Female Treated with Antineoplastons
Neurology and …, 2023
[3] Inoperable Optic Pathway Glioma: A Seven-Year-Old Male with> 35 Years Overall Survival Following Treatment with Antineoplastons
European Journal of …, 2023
[4] Recurrent Medulloblastoma: Complete Response and> than 21 Years and Five Months Overall Survival in a One-Year and Seven-Month-Old Male Treated …
… Review & Reports, 2023
[5] Newly diagnosed Glioblastoma: Partial Response and> 27 Years Overall Survival in a 37-Year-Old Male Treated with Antineoplastons
Recent Adv Clin …, 2022
[6] A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons
Cancer …, 2022
[7] Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and > 28 Years Survival in a Six Year and Nine-Month-Old Female Treated with Antineoplastons
International Journal of Clinical Oncology and Cancer Research, 2022
[8] Outcomes in Four Children with Persistent, Recurrent, and Progressive Gangliogliomas Treated in Phase II Studies with Antineoplastons A10 and AS2-1
Neurology and …, 2022
[9] Diffuse Intrinsic Pontine Glioma in an 11-Year-Old Female Treated with Antineoplastons: Complete Response and> 25 Years Survival
Pediatrics and …, 2021
[10] Resolution of clinical signs, a complete response, and long-term survival (> 23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic …
Biomed Res, 2021
[11] Long-term survival (27.7 years) following IV Antineoplaston Therapy (ANP) in a 36-year-old-female with a progressive diffuse intrinsic pontine glioma (DIPG)
Int J Radiol Imaging …, 2021
[12] Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design
2020
[13] Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy
Cancer and Clinical Oncology, 2019
[14] A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)
2016
[15] A phase II study of Antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08)
2015
[16] A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma—Final report (Protocol BT-15)
Cancer and Clinical Oncology, 2015
[17] Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy
Cancer and Clinical Oncology, 2015
[18] Long-Term Survival Over 21 Years and Pathologically Confirmed Complete Response in Pediatric Anaplastic Astrocytoma: A Case Report
J Neurol Stroke, 2015
[19] A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Newly-Diagnosed Anaplastic Astrocytoma-Final Report (Protocol BT-08)
Cancer and Clinical Oncology, 2015
[20] A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas. The report on non-diffuse intrinsic pontine glioma (Protocol BT-11)
2015
[21] A Phase II Study of Antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma: Final report (Protocol BT-08)
Cancer & Clinical …, 2015
[22] A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)
Journal of Cancer Therapy, 2014
[23] Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival
Journal of Cancer Therapy, 2014
[24] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[25] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[26] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[27] A Case of Sustained Objective Response of Recurrent/Progressive Diffuse Intrinsic Pontine Glioma with Phenylbutyrate and Targeted Agents
Journal of Cancer Therapy, 2014
[28] Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme
Journal of Cancer Therapy, 2014
[29] Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of …
2014
[30] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential …
2014
[31] Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy—a …
2014
[32] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for …
2014
Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top
  翻译: